This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Morphic Holding, Inc.
3/1/2021
Ladies and gentlemen, this is the operator. My name is Myra. Thank you for standing by and welcome to the Morphic Financial and Operational Results 2020 year-end conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. And to ask a question during the session, you will need to press star 1 on your telephone. If you require any further assistance, simply press star zero. With that, I would now like to hand the conference over to our first speaker, Chris Ehrman, Senior Vice President of Communications. Thank you, and please go ahead.
Thank you, Myra, and good morning, everyone. Thanks for attending Morphix's first investor call. Today, we will review our 2020 operational and financial results and also provide an update on the ongoing Phase I clinical trial of MorphO5-7 A little housekeeping. This morning we issued two press releases. The first reported results for the fourth quarter and full year ended December 31st, 2020, and the second announced the preliminary positive results from the single ascending dose portion of our ongoing phase one trial of Morpho 5-7. These releases, as well as our most recent corporate presentation, are available on the investor section of our website at morphictx.com. Also, before we begin, please note that we'll be making forward-looking statements as defined in the Private Securities Litigation Act of 1995. These statements will include, among other things, projections regarding the timing of key events related to Morphix's proprietary pipeline and financial guidance for 2021 and beyond. Actual results may differ materially from those projected in the forward-looking statements due to numerous risks and uncertainties that exist in Morphix operations, development efforts, and the business environment, including those factors discussed in our reports on 4Q and 10K and other documents filed with the Securities and Exchange Commission. The forward-looking statements contained in this call represent the judgment of Morphic as of today. Morphic disclaims any intent or obligation to update any forward-looking statement except to the extent required by law. Now, here's a quick roadmap to what we'll cover today since we're reporting the financial results, but we're also especially excited to discuss the data from the Morpho 5-7 study. Hosting the call today is Dr. Praveen Tiparneni, our Chief Executive Officer. Dr. Mark Sedren, our Chief Operating Officer and Chief Financial Officer, will cover our strategic and financial updates. Dr. Bruce Rogers, our chief scientific officer, will provide some background on the Mint platform and our emerging pipeline. And finally, Dr. Peter Lindy, our chief medical officer, will describe the data that we announced earlier this morning. We'll then open the line for Q&A, and with that, I'll hand the call over to Praveen.
Okay. Thank you, Chris. We are live. I'm Praveen Tipraneni. Welcome to Morphic Live, our very first conference call. For our first clinical stage program, we hit the ground running and with stunning data. That's why we decided to have this call. The news we are sharing today is what we've been working for since the founding of Morphic. Just on my way over here this morning, I was thinking, what a relief. I always thought our thesis for 057 was obvious. An orally available alpha-4, beta-7 inhibitor for IBD would be a huge asset for patients and for Morphic. We believed we could do this, but still a million things could have gone wrong. On any individual day, Bruce could have said, this is it. But day by day, his team solved one problem, the next one, the one after that, and if you solve enough problems, you get data like ours today. So what's the backstory here? We took a long shot several years ago to turn the table on an area with promise, but decades of consistent failure, oral integrin R&D. Because we and our founding scientists are the experts in integrin science. Today, we're able to share the evidence that the bet we made is paying off. It's one of those rare times, the culmination of years of work, where we get results even beyond our greatest expectations. The data we are discussing today are early but predictive. We'll explain why later. But before we give you all those details, a story just came to mind that illustrates what I think we've accomplished. What keeps you up at night? We've been asked this question many, many times, actually mainly from investors. For five years now, I have always had the exact same answer. It's pharmacokinetics, PK, predicting PK in humans based on preclinical data. It isn't rocket science. It's actually harder. NASA can land a rover on Mars barreling through its atmosphere at five kilometers per second, but you cannot reliably predict how drugs will behave when they hit humans. It was on my mind every day. Oral alpha-4 beta-7 inhibition to treat IBD is a totally obvious need, if you only had the molecule to get there. Well, Houston, Morphic's rocket scientists came through in a big way, leading to the data we reported this morning. Now, let me turn the call over to Mark, who will give an update on our operations and 2020 financial results.
You're reading a preview of the MORF Q4 2020 earnings call.
Free account.